Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says
MT newswire2026/10/09 15:0311:03 AM EDT, 10/09/2026 (MT Newswires) -- Exelixis' (EXEL) clinical trials evaluating Zanzalintinib in various types of cancer are highly likely to succeed, RBC Capital Markets analysts said in a Friday note. Analysts said that indications of ZanzaLantinib, including for colorectal cancer, have the potential to achieve $2.5 billion in sales by 2035. RBC said that the company has built an extensive and low clinical risk pipeline for ZanzaLantinib, and while a single indication may not capture over $1 billion in sales, it has seven programs that are set to provide business stability into the next decade. "We think the current price is already baking in a significant amount of success while discounting both commercial and clinical risks - so we expect shares to trade in line," analysts said. RBC retained a sector perform rating on the stock and increased its price target to $51 from $45. Price: 59.61, Change: +0.59, Percent Change: +1.00
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Silver Price Forecast: XAG/USD rises to near $53.00 as lower oil eases inflation pressure
Crypto prices
More
